Komal Jhaveri: Inavolisib approval for PIK3CA mutant ER+ metastatic breast cancer

Komal Jhaveri, Clinical Director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, shared a post on LinkedIn:

“Excited to see Inavolisib approval (Itovebi – pronounced Eye-Tove-Bee) for PIK3CA mutant ER + metastatic breast cancer.

Important to consider testing for PIK3CA mutation in the first line metastatic setting for those who have recurrence on or within 12 months of adjuvant endocrine therapy and to optimize toxicity management strategies.”

Amol Akhade shared about Inavolisib too.

“Inavolesib plus palbociclib plus fulvestrant has got approval by USFDA for ER resistant PIK3CA mutated Hr positive HER2 negative advanced breast cancer.

Some interesting thoughts about this trial Inavo120.

No OS yet. Toxicity issues present.

One more Option for endocrine resistant patients with PIK3CA mutation.”

Read further.

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.